- Home
- FDMT
as 11-05-2025 4:00pm EST
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Upcoming Earnings Alert:
Get ready for potential market movements as 4D Molecular Therapeutics Inc. FDMT prepares to release earnings report on 07 Nov 2025.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 391.8M | IPO Year: | 2020 |
| Target Price: | $30.11 | AVG Volume (30 days): | 933.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.23 - $12.34 | Next Earning Date: | 11-07-2025 |
| Revenue: | $33,000 | Revenue Growth: | -99.84% |
| Revenue Growth (this year): | 8572.97% | Revenue Growth (next year): | 6.05% |
Stock Insider Trading Activity of 4D Molecular Therapeutics Inc. (FDMT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bizily Scott | FDMT | Chief Legal Officer | Oct 24 '25 | Sell | $12.00 | 2,678 | $32,136.00 | 3,594 | |
| Bizily Scott | FDMT | Chief Legal Officer | Oct 16 '25 | Sell | $10.17 | 1,635 | $16,627.95 | 3,594 | |
| Bizily Scott | FDMT | Chief Legal Officer | Oct 9 '25 | Sell | $10.00 | 2,408 | $24,080.00 | 3,594 |
Latest 4D Molecular Therapeutics Inc. News
FDMT Breaking Stock News: Dive into FDMT Ticker-Specific Updates for Smart Investing
Insider Monkey
11 days ago
4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development
GlobeNewswire
19 days ago
4DMT Announces New Employment Inducement Grants
GlobeNewswire
23 days ago
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
MT Newswires
23 days ago
4D Molecular Therapeutics Receiving $11 Million in Funding for Cystic Fibrosis Study
GlobeNewswire
24 days ago
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
GlobeNewswire
2 months ago
4DMT Announces New Employment Inducement Grants
GlobeNewswire
5 months ago
4DMT to Participate in Upcoming Investor Conferences
Simply Wall St.
6 months ago
Spotlight On 3 Penny Stocks With Market Caps Under $500M
Compare FDMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FDMT 4D Molecular Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.